The strong Phase 3 efficacy and safety data de-risk ALXN1840 ahead of mid-2026 NDA submission. Monitor for FDA acceptance and priority review; positive outcome could drive significant upside for this single-asset biotech.
Price Chart
Executive Summary
Monopar Therapeutics presented new positive analyses from the Phase 3 FoCus trial of ALXN1840 in Wilson disease at EAN 2026, showing significant neurologic and global clinical improvement vs standard of care. The company plans to submit an NDA to the FDA in mid-2026, supporting a clear regulatory catalyst.
Key Facts
- ALXN1840 met primary endpoint of copper mobilization in Phase 3 FoCus trial.
- New analyses show significant neurologic improvement over time (p=0.006) and greater global clinical improvement (p<0.001) vs SOC.
- Drug-related serious adverse events occurred in 4.9% of patients; no treatment-related deaths.
- Monopar plans NDA submission to FDA for ALXN1840 in mid-2026.
Financial Impact
Positive data supports NDA filing; potential revenue if approved for Wilson disease (rare disease with ~1 in 30,000 prevalence). No financial figures disclosed.
Risk Factors
- Regulatory risk: FDA may require additional trials or issue a Complete Response Letter.
- Commercial risk: Wilson disease is rare; market uptake depends on pricing and competition from existing therapies.
- Financing risk: Monopar may need to raise capital to fund commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3318449 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $72.00 | awaiting T+60 | — | $71.84 (−0.22%) |
Oct 27, 2026 today | SC 13G | $72.00 | awaiting T+60 | — | $71.84 (−0.22%) |
Oct 5, 2026 22d ago | Insider Cluster | $79.57 | awaiting T+60 | — | $71.84 (+9.71%) |
Oct 1, 2026 26d ago | 144 | $77.97 | awaiting T+60 | — | $71.84 (−7.86%) |
Aug 28, 2026 8w ago | Insider Cluster | $111.93 | awaiting T+60 | — | $71.84 (−35.82%) |
Aug 27, 2026 8w ago | Insider Cluster | $111.89 | awaiting T+60 | — | $71.84 (−35.79%) |
Aug 25, 2026 9w ago | 144 | $113.72 | awaiting T+60 | — | $71.84 (−36.83%) |
Aug 12, 2026 10w ago | 8-K | $114.90 | awaiting T+60 | — | $71.84 (−37.48%) |
Aug 12, 2026 10w ago | Press Release | $114.90 | awaiting T+60 | — | $71.84 (−37.48%) |
Jul 22, 2026 13w ago | 8-K | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $71.84 (−36.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers